Abstract: Disclosed is an industrial method for simultaneously preparing Stevia rebaudiana chlorogenic acid and stevioside. The industrial method includes carrying out alcohol extraction on Stevia rebaudiana which is used as a raw material, and then adjusting the feed liquid state to allow chlorogenic acid to be in a free molecular state; carrying out extraction separation by a water-insoluble moderate-polarity organic solvent; enriching the Stevia rebaudiana chlorogenic acid in an organic layer; and enriching the stevioside in a water layer.

Abstract: A high-modulus low-shrinkage polyester industrial yarn obtained by subjecting a polyester to dissolution, washing and solid state polycondensation followed by spinning. The high-modulus low-shrinkage polyester industrial yarn has a dry heat shrinkage rate of 2.0±0.25% under test conditions of 177° C.×10 min×0.05 cN/dtex. The average value of the crystal volume Vc of the high-modulus low-shrinkage polyester industrial yarn is larger than 230 nm3. The high-modulus low-shrinkage polyester industrial yarn has a fiber modulus of ?100 cN/dtex. The polycondensation catalyst consists of magnesium ethylene glycol and antimony ethylene glycol, which has a small thermal degradation coefficient.

Abstract: A high-modulus low-shrinkage polyester industrial yarn obtained by subjecting a polyester to dissolution, washing and solid state polycondensation followed by spinning. The high-modulus low-shrinkage polyester industrial yarn has a dry heat shrinkage rate of 2.0±0.25% under test conditions of 177° C.×10 min×0.05 cN/dtex. The average value of the crystal volume VC of the high-modulus low-shrinkage polyester industrial yarn is larger than 230 mm3. The high-modulus low-shrinkage polyester industrial yarn has a fiber modulus of ?100 cN/dtex. The polycondensation catalyst consists of magnesium ethylene glycol and antimony ethylene glycol, which has a small thermal degradation coefficient.

Abstract: The invention relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in preparation of sensitizers of chemotherapeutic agents for cancers. The invention also relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides to protect normal or diseased tissues or organs from damage or further damage, and to pharmaceutical combinations including chemotherapeutic agents and PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in an amount effective for sensitization. Preferably, the pharmaceutical agents are selected from antibiotic and anti-metabolic agents or any combination thereof.